Therapy for sleep hypoventilation and central apnea syndromes

Bernardo J. Selim, Mithri R. Junna, Timothy Ian Morgenthaler

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

• Primary Central Sleep Apnea (CSA): We would recommend a trial of Positive Airway Pressure (PAP), acetazolamide, or zolpidem based on thorough consideration of risks and benefits and incorporation of patient preferences. • Central Sleep Apnea Due to Cheyne-Stokes Breathing Pattern in Congestive Heart Failure (CSR-CHF): We would recommend PAP devices such as continuous positive airway pressure (CPAP) or adaptive servo-ventilation (ASV) to normalize sleep-disordered breathing after optimizing treatment of heart failure. Oxygen may also be an effective therapy. Acetazolamide and theophylline may be considered if PAP or oxygen is not effective. • Central Sleep Apnea due to High-Altitude Periodic Breathing: We would recommend descent from altitude or supplemental oxygen. Acetazolamide may be used when descent or oxygen are not feasible, or in preparation for ascent to high altitude. Slow ascent may be preventative. • Central Sleep Apnea due to Drug or Substance: If discontinuation or reduction of opiate dose is not feasible or effective, we would recommend a trial of CPAP, and if not successful, treatment with ASV. If ASV is ineffective or if nocturnal hypercapnia develops, bilevel positive airway pressure-spontaneous timed mode (BPAP-ST) is recommended. • Obesity hypoventilation syndrome: We would recommend an initial CPAP trial. If hypoxia or hypercapnia persists on CPAP, BPAP, BPAP-ST or average volume assured pressure support (AVAPSTM) is recommended. Tracheostomy with nocturnal ventilation should be considered when the above measures are not effective. Weight loss may be curative. • Neuromuscular or chest wall disease: We would recommend early implementation of BPAP-ST based on thorough consideration of risks and benefits and patient preferences. AVAPSTM may also be considered. We recommend close follow up due to disease progression.

Original languageEnglish (US)
Pages (from-to)427-437
Number of pages11
JournalCurrent Treatment Options in Neurology
Volume14
Issue number5
DOIs
StatePublished - Oct 2012

Fingerprint

Central Sleep Apnea
Hypoventilation
Continuous Positive Airway Pressure
Pressure
Acetazolamide
Ventilation
Oxygen
Hypercapnia
Patient Preference
Therapeutics
Opiate Alkaloids
Respiration
Obesity Hypoventilation Syndrome
Heart Failure
Tracheostomy
Sleep Apnea Syndromes
Thoracic Wall
Theophylline
Treatment Failure
Disease Progression

Keywords

  • Alveolar hypoventilation syndromes
  • Central apnea syndromes
  • Cheyne-Stokes breathing pattern
  • Drugs
  • High-altitude periodic breathing
  • Narcotics
  • Sleep hypoventilation
  • Sleep-related hypoventilation syndromes
  • Therapy

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Therapy for sleep hypoventilation and central apnea syndromes. / Selim, Bernardo J.; Junna, Mithri R.; Morgenthaler, Timothy Ian.

In: Current Treatment Options in Neurology, Vol. 14, No. 5, 10.2012, p. 427-437.

Research output: Contribution to journalArticle

@article{292e658234704569801865baa9c2c4d8,
title = "Therapy for sleep hypoventilation and central apnea syndromes",
abstract = "• Primary Central Sleep Apnea (CSA): We would recommend a trial of Positive Airway Pressure (PAP), acetazolamide, or zolpidem based on thorough consideration of risks and benefits and incorporation of patient preferences. • Central Sleep Apnea Due to Cheyne-Stokes Breathing Pattern in Congestive Heart Failure (CSR-CHF): We would recommend PAP devices such as continuous positive airway pressure (CPAP) or adaptive servo-ventilation (ASV) to normalize sleep-disordered breathing after optimizing treatment of heart failure. Oxygen may also be an effective therapy. Acetazolamide and theophylline may be considered if PAP or oxygen is not effective. • Central Sleep Apnea due to High-Altitude Periodic Breathing: We would recommend descent from altitude or supplemental oxygen. Acetazolamide may be used when descent or oxygen are not feasible, or in preparation for ascent to high altitude. Slow ascent may be preventative. • Central Sleep Apnea due to Drug or Substance: If discontinuation or reduction of opiate dose is not feasible or effective, we would recommend a trial of CPAP, and if not successful, treatment with ASV. If ASV is ineffective or if nocturnal hypercapnia develops, bilevel positive airway pressure-spontaneous timed mode (BPAP-ST) is recommended. • Obesity hypoventilation syndrome: We would recommend an initial CPAP trial. If hypoxia or hypercapnia persists on CPAP, BPAP, BPAP-ST or average volume assured pressure support (AVAPSTM) is recommended. Tracheostomy with nocturnal ventilation should be considered when the above measures are not effective. Weight loss may be curative. • Neuromuscular or chest wall disease: We would recommend early implementation of BPAP-ST based on thorough consideration of risks and benefits and patient preferences. AVAPSTM may also be considered. We recommend close follow up due to disease progression.",
keywords = "Alveolar hypoventilation syndromes, Central apnea syndromes, Cheyne-Stokes breathing pattern, Drugs, High-altitude periodic breathing, Narcotics, Sleep hypoventilation, Sleep-related hypoventilation syndromes, Therapy",
author = "Selim, {Bernardo J.} and Junna, {Mithri R.} and Morgenthaler, {Timothy Ian}",
year = "2012",
month = "10",
doi = "10.1007/s11940-012-0188-3",
language = "English (US)",
volume = "14",
pages = "427--437",
journal = "Current Treatment Options in Neurology",
issn = "1092-8480",
publisher = "Current Science, Inc.",
number = "5",

}

TY - JOUR

T1 - Therapy for sleep hypoventilation and central apnea syndromes

AU - Selim, Bernardo J.

AU - Junna, Mithri R.

AU - Morgenthaler, Timothy Ian

PY - 2012/10

Y1 - 2012/10

N2 - • Primary Central Sleep Apnea (CSA): We would recommend a trial of Positive Airway Pressure (PAP), acetazolamide, or zolpidem based on thorough consideration of risks and benefits and incorporation of patient preferences. • Central Sleep Apnea Due to Cheyne-Stokes Breathing Pattern in Congestive Heart Failure (CSR-CHF): We would recommend PAP devices such as continuous positive airway pressure (CPAP) or adaptive servo-ventilation (ASV) to normalize sleep-disordered breathing after optimizing treatment of heart failure. Oxygen may also be an effective therapy. Acetazolamide and theophylline may be considered if PAP or oxygen is not effective. • Central Sleep Apnea due to High-Altitude Periodic Breathing: We would recommend descent from altitude or supplemental oxygen. Acetazolamide may be used when descent or oxygen are not feasible, or in preparation for ascent to high altitude. Slow ascent may be preventative. • Central Sleep Apnea due to Drug or Substance: If discontinuation or reduction of opiate dose is not feasible or effective, we would recommend a trial of CPAP, and if not successful, treatment with ASV. If ASV is ineffective or if nocturnal hypercapnia develops, bilevel positive airway pressure-spontaneous timed mode (BPAP-ST) is recommended. • Obesity hypoventilation syndrome: We would recommend an initial CPAP trial. If hypoxia or hypercapnia persists on CPAP, BPAP, BPAP-ST or average volume assured pressure support (AVAPSTM) is recommended. Tracheostomy with nocturnal ventilation should be considered when the above measures are not effective. Weight loss may be curative. • Neuromuscular or chest wall disease: We would recommend early implementation of BPAP-ST based on thorough consideration of risks and benefits and patient preferences. AVAPSTM may also be considered. We recommend close follow up due to disease progression.

AB - • Primary Central Sleep Apnea (CSA): We would recommend a trial of Positive Airway Pressure (PAP), acetazolamide, or zolpidem based on thorough consideration of risks and benefits and incorporation of patient preferences. • Central Sleep Apnea Due to Cheyne-Stokes Breathing Pattern in Congestive Heart Failure (CSR-CHF): We would recommend PAP devices such as continuous positive airway pressure (CPAP) or adaptive servo-ventilation (ASV) to normalize sleep-disordered breathing after optimizing treatment of heart failure. Oxygen may also be an effective therapy. Acetazolamide and theophylline may be considered if PAP or oxygen is not effective. • Central Sleep Apnea due to High-Altitude Periodic Breathing: We would recommend descent from altitude or supplemental oxygen. Acetazolamide may be used when descent or oxygen are not feasible, or in preparation for ascent to high altitude. Slow ascent may be preventative. • Central Sleep Apnea due to Drug or Substance: If discontinuation or reduction of opiate dose is not feasible or effective, we would recommend a trial of CPAP, and if not successful, treatment with ASV. If ASV is ineffective or if nocturnal hypercapnia develops, bilevel positive airway pressure-spontaneous timed mode (BPAP-ST) is recommended. • Obesity hypoventilation syndrome: We would recommend an initial CPAP trial. If hypoxia or hypercapnia persists on CPAP, BPAP, BPAP-ST or average volume assured pressure support (AVAPSTM) is recommended. Tracheostomy with nocturnal ventilation should be considered when the above measures are not effective. Weight loss may be curative. • Neuromuscular or chest wall disease: We would recommend early implementation of BPAP-ST based on thorough consideration of risks and benefits and patient preferences. AVAPSTM may also be considered. We recommend close follow up due to disease progression.

KW - Alveolar hypoventilation syndromes

KW - Central apnea syndromes

KW - Cheyne-Stokes breathing pattern

KW - Drugs

KW - High-altitude periodic breathing

KW - Narcotics

KW - Sleep hypoventilation

KW - Sleep-related hypoventilation syndromes

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84870837513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870837513&partnerID=8YFLogxK

U2 - 10.1007/s11940-012-0188-3

DO - 10.1007/s11940-012-0188-3

M3 - Article

C2 - 22923141

AN - SCOPUS:84870837513

VL - 14

SP - 427

EP - 437

JO - Current Treatment Options in Neurology

JF - Current Treatment Options in Neurology

SN - 1092-8480

IS - 5

ER -